Akari Therapeutics Stock Forecast, Price & News

Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

How has Akari Therapeutics' stock been impacted by COVID-19?

Akari Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AKTX shares have decreased by 7.1% and is now trading at $1.43.
View which stocks have been most impacted by COVID-19.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totaling 144,500 shares, an increase of 113.4% from the December 15th total of 67,700 shares. Based on an average daily volume of 109,400 shares, the days-to-cover ratio is currently 1.3 days.
View Akari Therapeutics' Short Interest.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, April 19th 2022.
View our earnings forecast for Akari Therapeutics.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) announced its earnings results on Friday, December, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter.
View Akari Therapeutics' earnings history.

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the following people:

• Clive Stuart Richardson, CEO, Chief Operating Officer & Director
• Torsten Hombeck, Chief Financial & Accounting Officer
• Miles Nunn, Chief Scientific Officer
• Wynne Weston-Davies, Medical Director

Who are some of Akari Therapeutics' key competitors?

Some companies that are related to Akari Therapeutics include Immunic (IMUX), Verastem (VSTM), Cue Biopharma (CUE), Thorne Healthtech (THRN), Kamada (KMDA), Connect Biopharma (CNTB), eFFECTOR Therapeutics (EFTR), KalVista Pharmaceuticals (KALV), Provention Bio (PRVB), Altimmune (ALT), Evelo Biosciences (EVLO), Rallybio (RLYB), CytomX Therapeutics (CTMX), Nabriva Therapeutics (NBRV) and Sierra Oncology (SRRA).
View all of AKTX's competitors.

What other stocks do shareholders of Akari Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.43.

How much money does Akari Therapeutics make?

Akari Therapeutics has a market capitalization of $74.23 million. The biopharmaceutical company earns $-17.08 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Akari Therapeutics have?

Akari Therapeutics employs 2,020 workers across the globe.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is www.akaritx.com.

Where are Akari Therapeutics' headquarters?

Akari Therapeutics is headquartered at 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 442080040261, via email at [email protected], or via fax at 646-843-9352.